Welcome to our dedicated page for Fresenius Med Cr SEC filings (Ticker: FMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to separate U.S. dialysis clinic margins from overseas device sales in a single 300-page report can feel impossible. Fresenius Medical Care’s integrated business model makes its disclosures uniquely complex—Medicare reimbursement tables sit next to dialyzer manufacturing data, while international currency risks weave through every footnote.
Our platform solves that maze. Stock Titan’s AI reads each Fresenius Medical Care annual report 10-K simplified, flags where product vs. service revenue diverge, and summarizes the risk-factor language in plain English. Real-time alerts surface every Fresenius Medical Care insider trading Form 4 transactions so you can track executive stock moves without refreshing EDGAR. Need fast numbers between annual cycles? The system breaks down each Fresenius Medical Care quarterly earnings report 10-Q filing into segment revenue, clinic count, and operating income—complete with trend charts.
All filing types are covered the moment they hit the SEC: 8-Ks for recall notices (“Fresenius Medical Care 8-K material events explained”), proxy statements to decode Fresenius Medical Care executive compensation, and real-time Fresenius Medical Care Form 4 insider transactions. You’ll also find:
- AI-powered summaries that explain complicated renal-care disclosures simply
- Keyword search across historical documents to compare segment growth
- Automatic highlights of litigation updates and reimbursement changes
Whether you’re monitoring clinic utilization trends, watching Fresenius Medical Care earnings report filing analysis, or just need understanding Fresenius Medical Care SEC documents with AI, this page keeps every material disclosure at your fingertips—no more hunting through dense PDFs.
Fresenius Medical Care AG reports interim operating updates and segment changes. As of June 1, 2025, the company created a new Value‑Based Care segment, recognizing full‑risk arrangements under IFRS 17 with premiums and claim costs presented separately. For the nine months ended September 30, 2025, 16% of consolidated revenue was attributable to U.S. federally funded programs.
Capital efficiency remained modest: ROIC was 4.1%, or 4.9% excluding Legacy Portfolio Optimization costs, based on NOPAT of €1,101 M and average invested capital of €27,150 M. Total assets were €30,887 M and invested capital €25,471 M as of September 30, 2025.
Regulatory dynamics continue to influence U.S. operations. CMS proposed to terminate the mandatory ETC model on December 31, 2025; 971 U.S. facilities (about 35%) are currently in ETC regions and the program to date produced a net positive payment adjustment. The company participates in 21 KCEs, with approximately 52,000 patients aligned as of September 2025, reflecting scale in value‑based kidney care.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.
FAQ
What is the current stock price of Fresenius Med Cr (FMS)?
What is the market cap of Fresenius Med Cr (FMS)?
